Tempus AI

Tempus AI FCF Growth

The Year-over-Year Free Cash Flow Growth of Tempus AI (TEM) as of Nov 20, 2026 is -16.19 %. In the previous year, Year-over-Year Free Cash Flow Growth was 15.18 % — a change of -206.68% (lower).

FCF Growth

-16.19 %

YoY

-206.68%

Last updated:

Year-over-Year Free Cash Flow Growth of Tempus AI is 2025 -16.19 % . Year-over-Year Free Cash Flow Growth of Tempus AI was 2024 15.18 % . It decreases by -206.68% lower compared to the previous year.

The Tempus AI FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2020
-63.98 USD
Jan 1, 2021
-1.72 USD
Jan 1, 2022
16.61 USD
Jan 1, 2023
-33.43 USD
Jan 1, 2024
15.18 USD
Jan 1, 2025
-16.19 USD
The Tempus AI FCF Growth history
YEARFCF GrowthYoY
-16.19 %-206.68%
15.18 %-145.40%
-33.43 %-301.21%
16.61 %-1,068.55%
-1.72 %-97.32%
-63.98 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

Year-over-Year Free Cash Flow Growth of Tempus AI is -16.19 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Tempus AI since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Tempus AI historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Tempus AI

All Key Metrics — Tempus AI